MBX Biosciences Inc（MBX）财务数据MBXMBX Biosciences Inc

Evaluating the bottom line, MBX Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -33.17%, provide a clear picture of how effectively MBX converts its operational activities into shareholder value.

In the context of the broader market, MBX competes directly with industry leaders such as ADMA and BEAM. With a market capitalization of $2.53B, it holds a leading position in the sector. When comparing efficiency, MBX's gross margin of N/A stands against ADMA's 69.31% and BEAM's 100.00%. Such benchmarking helps identify whether MBX Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

MBX has reported consistent net losses, with Q2 2026 showing a net loss of $37.1 million, up from $19.4 million in Q2 2025, indicating worsening financial health.